Maze Therapeutics
Manufacturing · California, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
171 Oyster Point Blvd Ste 300, South San...Phone Number
(650) 291-4889Website
www.mazetx.comRevenue
$20 MillionStock Symbol
MAZEIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
4
1
1
1
1
1
About Maze Therapeutics
Maze Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity.Explore more
Maze Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Maze Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Maze Therapeutics recently announced quarterly report
Product Launch: Get notified when Maze Therapeutics launches new products
Congratulate Masked Content for being promoted to Masked Content at Maze Therapeutics
Check if Maze Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Click to see if Maze Therapeutics had a recent Job posting/layoffs
Maze Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Maze Therapeutics has new funding data
Check out if Maze Therapeutics is spiking on competitors!
Recommended Actions
Reach out to Masked Content who joined Maze Therapeutics as Masked Content
Find 2 more new buyers
Compare Similar Companies to Maze Therapeutics
Compare insights from companies similar to Maze Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Maze Therapeutics
$20M
51-200
Public
$496M
2018
HB
Harold BernsteinPresident, Research & Chief Medical Officer, Development
Company Profile Activity
Activity Insights
Maze Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Maze Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Maze Therapeutics.
Maze Therapeutics financials insights
Gather financial insights about Maze Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2019
Series A
$191M
2022
Unspecified
$190M
2024
Series D
$115M
Maze Therapeutics Tech Stack
A closer look at the technologies used by Maze Therapeutics
Most Recent Scoops
Left Company
Executive Move
Executive Moves, Left Company
Project
Maze Therapeutics is conducting the Phase II HORIZON study for MZE829, an open-label basket study enrolling patients with G1 or G2 APOL1 variants across non-diabetic, diabetic, and FSGS subtypes, with a three-month treatment period followed by one-month follow-up, targeting 10 to 15 patients per subtype and evaluating safety, tolerability, and urinary albumin-to-creatinine ratio as a secondary efficacy endpoint.
Project
reported preclinical data for MZE782 in chronic kidney disease demonstrating that MZE782 monotherapy exceeded SGLT2 inhibitor (dapagliflozin) monotherapy in UACR reduction in in vivo models, with the combination of MZE782 and a SGLT2 inhibitor essentially normalizing both UACR and the kidney injury marker KIM-1 to control levels.
Project
Maze Therapeutics is targeting a full HORIZON study readout for MZE829 by the end of 2025 or early 2026, with Phase II and End-of-Phase II meetings with regulatory agencies in planning and a pivotal study initiation planned for the first half of 2027, supported by the PARASOL Initiative academic working group actively defining regulatory endpoints for APOL1-mediated kidney disease approval pathways.
Clinical Operations
Open Position
Maze Therapeutics News & Media
Maze Therapeutics (MAZE): 8 Oversold Stocks to Buy Right Now
Maze Therapeutics Inc. (NASDAQ:MAZE) is one of the oversold stocks to buy right now. On May 12, Maze Therapeutics highlighted in their corporate and financial update positive topline data from the Phase 2 HORIZON trial of MZE829. The trial evaluated the oral inhibitor in patients with APOL1-mediated kidney disease/AMKD. The results provided clinical proof-of-concept, showing […]Maze Therapeutics' CEO Sold Over 30,000 Company Shares. What Does That Mean for Investors?
This clinical-stage biotech advancing precision medicines reported a notable insider sale amid strong one-year share performance.Maze Therapeutics to Participate in Two Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced that Jason Coloma, Ph.D., chief executive officer of Maze Therapeutics, will participate in two upcoming investor conferences:Maze Therapeutics Stock Still Up 180% After March Tumble. One Fund Just Disclosed Selling $3 Million in Shares
Maze Therapeutics is a U.S. biotech advancing clinical-stage precision medicines for renal and metabolic diseases.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Maze Therapeutics
Sign Up For FreeTo access detailed company insights
Maze Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity.... Read More
